{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:16:16Z","timestamp":1787829376896,"version":"build-2784847793"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR)-targeted near-infrared photoimmunotherapy (NIR-PIT) is an emerging drug-device modality that enables spatially selective tumor cell killing through antibody-photoabsorber conjugation and localized light activation. Although clinical translation has advanced in selected settings, particularly head and neck squamous cell carcinoma (HNSCC), barriers and enablers influencing broader implementation across solid tumors have not been systematically mapped. This review focuses specifically on the IR700 (IRDye700DX)-based conjugate cetuximab sarotalocan (RM-1929\/ASP-1929), which is the only NIR-PIT construct to have advanced into clinical use, while acknowledging the broader and rapidly expanding photoimmunotherapy landscape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize and characterize the biological, technical, clinical, and system-level factors that facilitate or hinder the clinical translation of EGFR-targeted NIR-PIT across EGFR-expressing advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted in accordance with PRISMA-ScR guidelines. Comprehensive searches of PubMed, Embase, Scopus, ClinicalTrials.gov, and the Cochrane Library identified 28 eligible studies, including preclinical investigations, early-phase clinical trials, observational studies, and case reports or series. Data were charted and synthesized thematically, with study quality appraised to inform interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preclinical studies consistently demonstrated light-dependent, EGFR-selective cytotoxicity and identified non-linear dose\u2013response relationships that support standardized light dosing strategies. Clinical translation has been most successful in recurrent or unresectable HNSCC, facilitated by tumor accessibility, multidisciplinary workflows, and regulatory approval in Japan. Technical enablers included endoscopic and navigation-assisted light delivery, real-time fluorescence imaging, and the feasibility of repeat treatment without cumulative toxicity. Key barriers included limited light penetration, anatomical constraints, reliance on specialized equipment, and restricted applicability to deep-seated or diffuse disease. Although most adverse events were localized and manageable, rare but serious complications reported across multiple case studies represent an important translational challenge. Evidence outside HNSCC remains sparse and is largely confined to preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EGFR-targeted NIR-PIT has achieved meaningful clinical translation within a narrow but well-defined therapeutic niche, supported by strong mechanistic rationale and growing real-world experience. Broader adoption is constrained by biological, technical, regulatory and system-level barriers, as well as gaps in comparative effectiveness, long-term outcomes, and health-economic evidence. Addressing these challenges through targeted clinical trials, improved patient selection, and implementation-focused research will be essential to advance NIR-PIT toward wider clinical integration.<\/jats:p>\n                    <jats:p>Statement of Significance This scoping review is the first to systematically map biological, technical, clinical, and regulatory barriers and enablers shaping the translation of EGFR-targeted near-infrared photoimmunotherapy. By reframing efficacy evidence through an implementation lens, it provides a practical framework to guide future clinical adoption and translational research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag026","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:48:24Z","timestamp":1780487304000},"page":"407-419","source":"Crossref","is-referenced-by-count":1,"title":["Epidermal growth factor receptor\u2013targeted near-infrared photoimmunotherapy for epidermal growth factor receptor\u2013expressing advanced solid tumors: a scoping review of barriers and enablers to clinical translation"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5791-301X","authenticated-orcid":false,"given":"Emmanuel O","family":"Oisakede","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust , Leeds ,","place":["LS9 7TF, United Kingdom"]},{"name":"Department of Health Research, University of Leeds , Leeds , LS2 9JT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawunmi O","family":"Oyedeji","sequence":"additional","affiliation":[{"name":"Department of Research and Innovation, The Christie NHS Foundation Trust , Manchester , M20 4BX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odunola F","family":"Atitebi","sequence":"additional","affiliation":[{"name":"Can-Survive UK , Manchester , M15 5DD,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijomah","family":"Ugbomah","sequence":"additional","affiliation":[{"name":"Department of Transformation and Quality Improvement, University Hospitals of Northamptonshire , Kettering , NN16 8UZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Olawade","sequence":"additional","affiliation":[{"name":"Department of Research and Innovation, Medway NHS Foundation Trust , Gillingham ME75NY ,","place":["United Kingdom"]},{"name":"Department of Public Health, York St John University , London , E14 2BA,","place":["United Kingdom"]},{"name":"Department of Allied and Public Health, School of Health, Sport and Bioscience, University of East London , London , E16 2RD,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026081210261898500_ref1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026081210261898500_ref2","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1200\/jco.2005.04.8306","article-title":"Epidermal growth factor receptor biology in head and neck cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026081210261898500_ref3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell\u2013selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat Med"},{"key":"2026081210261898500_ref4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/pharmaceutics17060716","article-title":"Next-generation cancer treatment: Photoimmunotherapy\u2019s promise for Unresectable head and neck cancers","volume":"17","author":"Ailioaie","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026081210261898500_ref5","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.18632\/oncotarget.14425","article-title":"Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity","volume":"8","author":"Ogawa","year":"2017","journal-title":"Oncotarget"},{"key":"2026081210261898500_ref6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","article-title":"A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma","volume":"26","author":"Tahara","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2026081210261898500_ref7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hed.70014","article-title":"Safety and efficacy findings from a phase Ib II study of ASP-1929 Photoimmunotherapy with Pembrolizumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"48","author":"Cognetti","year":"2025","journal-title":"Head Neck"},{"key":"2026081210261898500_ref8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s10120-025-01623-9","article-title":"A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)","volume":"28","author":"Kadota","year":"2025","journal-title":"Gastric Cancer"},{"key":"2026081210261898500_ref9","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"2026081210261898500_ref10","volume-title":"Japan Approves Photoimmunotherapy for Head and Neck Cancer | Center for Cancer Research","author":"National Cancer Institute (NCI)"},{"key":"2026081210261898500_ref11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026081210261898500_ref12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.11124\/jbies-22-00123","article-title":"Recommendations for the extraction, analysis, and presentation of results in scoping reviews","volume":"21","author":"Pollock","year":"2023","journal-title":"JBI Evid Synth"},{"key":"2026081210261898500_ref13","volume-title":"Risk of Bias Tools\u2014Original (2016) Version of ROBINS-I","author":"Cochrane Bias Method Group"},{"key":"2026081210261898500_ref14","volume-title":"Critical Appraisal Checklists","author":"CASP"},{"key":"2026081210261898500_ref15","volume-title":"Critical Appraisal Tools","author":"Joanna Briggs Institute (JBI)"},{"key":"2026081210261898500_ref16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026081210261898500_ref17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000521435","article-title":"Photoimmunotherapy for managing recurrent laryngeal cancer cervical lesions: a case report","volume":"15","author":"Okamoto","year":"2022","journal-title":"Case Rep Oncol"},{"key":"2026081210261898500_ref18","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/cancers14184413","article-title":"Quality-of-life evaluation of patients with Unresectable locally advanced or locally recurrent head and neck carcinoma treated with head and neck Photoimmunotherapy","volume":"14","author":"Okamoto","year":"2022","journal-title":"Cancers"},{"key":"2026081210261898500_ref19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21873\/invivo.12799","article-title":"Case treated with Photoimmunotherapy under a navigation system for recurrent lesions of the lateral pterygoid muscle","volume":"36","author":"Okamoto","year":"2022","journal-title":"In Vivo"},{"key":"2026081210261898500_ref20","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.3390\/cancers14225662","article-title":"Near-infrared Photoimmunotherapy for oropharyngeal cancer","volume":"14","author":"Nishikawa","year":"2022","journal-title":"Cancers"},{"key":"2026081210261898500_ref21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/1535-7163.mct-22-0313","article-title":"Near-infrared Photoimmunotherapy targeting Podoplanin-expressing cancer cells and cancer-associated fibroblasts","volume":"22","author":"Kato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026081210261898500_ref22","doi-asserted-by":"publisher","first-page":"114390","DOI":"10.1016\/j.biopha.2023.114390","article-title":"Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases","volume":"160","author":"Inagaki","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026081210261898500_ref23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.anl.2022.06.004","article-title":"Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma","volume":"50","author":"Omura","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"2026081210261898500_ref24","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1111\/cas.15965","article-title":"Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700","volume":"114","author":"Takao","year":"2023","journal-title":"Cancer Sci"},{"key":"2026081210261898500_ref25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/healthcare11060924","article-title":"A case series on pain accompanying Photoimmunotherapy for head and neck cancer","volume":"11","author":"Shibutani","year":"2023","journal-title":"Healthcare"},{"key":"2026081210261898500_ref26","doi-asserted-by":"publisher","first-page":"e0136829","DOI":"10.1371\/journal.pone.0136829","article-title":"Near infrared Photoimmunotherapy targeting EGFR positive triple negative breast cancer: optimizing the conjugate-light regimen","volume":"10","author":"Nagaya","year":"2015","journal-title":"PloS One"},{"key":"2026081210261898500_ref27","doi-asserted-by":"publisher","first-page":"19026","DOI":"10.18632\/oncotarget.24876","article-title":"Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody","volume":"9","author":"Nagaya","year":"2018","journal-title":"Oncotarget"},{"key":"2026081210261898500_ref28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21873\/cdp.10291","article-title":"Two cases of emergency tracheostomy after head and neck Photoimmunotherapy","volume":"4","author":"Okamoto","year":"2024","journal-title":"Cancer Diagn Progn"},{"key":"2026081210261898500_ref29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1159\/000537898","article-title":"A case of Photoimmunotherapy for nasopharyngeal carcinoma requiring emergency tracheostomy","volume":"17","author":"Kushihashi","year":"2024","journal-title":"Case Rep Oncol"},{"key":"2026081210261898500_ref30","doi-asserted-by":"publisher","first-page":"e74742","DOI":"10.7759\/cureus.74742","article-title":"Near infrared Photoimmunotherapy for Locoregionally recurrent oropharyngeal squamous cell carcinoma at Tongue Base after Chemoradiotherapy: a case report and literature review","volume":"16","author":"Tamagawa","year":"2024","journal-title":"Cureus"},{"key":"2026081210261898500_ref31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000535597","article-title":"Lemierre\u2019s syndrome after head and neck Photoimmunotherapy for local recurrence of nasopharyngeal carcinoma","volume":"17","author":"Nishimura","year":"2024","journal-title":"Case Rep Oncol"},{"key":"2026081210261898500_ref32","doi-asserted-by":"publisher","first-page":"104719","DOI":"10.1016\/j.pdpdt.2025.104719","article-title":"Near-infrared photoimmunotherapy for recurrent cancer at the base of the tongue","volume":"54","author":"Makino","year":"2025","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2026081210261898500_ref33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40780-025-00465-y","article-title":"Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report","volume":"11","author":"Kado","year":"2025","journal-title":"J Pharm Health Care Sci"},{"key":"2026081210261898500_ref34","doi-asserted-by":"publisher","first-page":"102260","DOI":"10.1016\/j.rmcr.2025.102260","article-title":"Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab\u2013sarotalocan sodium in a patient with oropharyngeal cancer: a case report","volume":"57","author":"Takuma","year":"2025","journal-title":"Respir Med Case Rep"},{"key":"2026081210261898500_ref35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.anl.2025.06.008","article-title":"Interstitial pneumonia caused by Photoimmunotherapy with cetuximab-IR700 conjugate","volume":"52","author":"Suekata","year":"2025","journal-title":"Auris Nasus Larynx"},{"key":"2026081210261898500_ref36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.anl.2025.05.001","article-title":"Evaluation of real-time pharmacokinetics using fluorescence imaging system in near-infrared photoimmunotherapy for head and neck cancer","volume":"52","author":"Ueda","year":"2025","journal-title":"Auris Nasus Larynx"},{"key":"2026081210261898500_ref37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/cancers18010162","article-title":"Recovery of IR700 fluorescence after near-infrared Photoimmunotherapy: discovery and mechanistic insights","volume":"18","author":"Tanaka","year":"2026","journal-title":"Cancers"},{"key":"2026081210261898500_ref38","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.3390\/cancers14164042","article-title":"Optimal light dose for hEGFR-targeted near-infrared Photoimmunotherapy","volume":"14","author":"Furumoto","year":"2022","journal-title":"Cancers"},{"key":"2026081210261898500_ref39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.anl.2025.01.005","article-title":"Photoimmunotherapy for head and neck cancer: a systematic review","volume":"52","author":"Okamoto","year":"2025","journal-title":"Auris Nasus Larynx"},{"key":"2026081210261898500_ref40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00262-021-03124-x","article-title":"Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy","volume":"71","author":"Okada","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026081210261898500_ref41","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-infrared Photoimmunotherapy of cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc Chem Res"},{"key":"2026081210261898500_ref42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","article-title":"Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity","volume":"33","author":"Kobayashi","year":"2020","journal-title":"Int Immunol"},{"key":"2026081210261898500_ref43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/abt\/tbac024","article-title":"The emergence of AntibodyPlus: the future trend of antibody-based therapeutics","volume":"5","author":"Zhu","year":"2022","journal-title":"Antib Ther"},{"key":"2026081210261898500_ref44","doi-asserted-by":"publisher","first-page":"103325","DOI":"10.1016\/j.critrevonc.2021.103325","article-title":"Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: challenges and potentials for human applications","volume":"161","author":"Paraboschi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026081210261898500_ref45","doi-asserted-by":"publisher","first-page":"103501","DOI":"10.1016\/j.ebiom.2021.103501","article-title":"Near infrared photoimmunotherapy for cancers: a translational perspective","volume":"70","author":"Maruoka","year":"2021","journal-title":"EBioMedicine"},{"key":"2026081210261898500_ref46","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/1538-7445.AM2026-4297","article-title":"COX-2\/PGE2-driven, photoimmunotherapy-induced edema is reduced by prophylactic NSAIDs in mouse tumor models","volume":"86","author":"Amantea","journal-title":"Cancer Res"},{"key":"2026081210261898500_ref47","doi-asserted-by":"publisher","first-page":"20200110","DOI":"10.1002\/viw.20200110","article-title":"Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment","volume":"3","author":"Monaco","year":"2021","journal-title":"VIEW"},{"key":"2026081210261898500_ref48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/abt\/tbaf001","article-title":"Near-infrared Photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research","volume":"8","author":"Allen","year":"2025","journal-title":"Antib Ther"},{"key":"2026081210261898500_ref49","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jjco\/hyaf069","article-title":"Near-infrared photoimmunotherapy: basics and clinical application","volume":"55","author":"Okada","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026081210261898500_ref50","article-title":"Rakuten medical completes technology transfer of IR700 manufacturing and establishes exclusive position in its supply","author":"Rakuten Medical, Inc","year":"4  2025"},{"key":"2026081210261898500_ref51","article-title":"Rakuten medical expands academic access to IR700 dye through fee-only provision, greater publication freedom and expanded IP & commercialisation opportunities","author":"Rakuten Medical, Inc","year":"20, 2026"},{"key":"2026081210261898500_ref52","volume-title":"Benzoporphyrin Analogs, Conjugates, and Methods of Use Thereof","author":"Sadiki","year":"2024"},{"key":"2026081210261898500_ref53","volume-title":"Antibody-Photosensitive Substance Conjugate","author":"Iwashiro","year":"2025"},{"key":"2026081210261898500_ref54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/1535-7163.MCT-17-0953","article-title":"An infrared dye-conjugated virus-like particle for the treatment of primary uveal melanoma","volume":"17","author":"Kines","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026081210261898500_ref55","volume-title":"CoMpass phase 3 trial of belzupacap sarotalocan (bel-Sar) for small choroidal melanoma","author":"Aura Biosciences, Inc"},{"key":"2026081210261898500_ref56","volume-title":"Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as a First-Line Treatment for Early-Stage Choroidal Melanoma\u2014Aura Biosciences","author":"Aura Biosciences, Inc"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag026\/68479336\/tbag026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/407\/68479336\/tbag026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/407\/68479336\/tbag026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:27:53Z","timestamp":1786544873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/3\/407\/8702842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag026","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]}}}